Dextro-amphetamine diminishes negative symptoms in schizophrenia

Int Clin Psychopharmacol. 1988 Apr;3(2):111-21. doi: 10.1097/00004850-198804000-00002.

Abstract

Thirty schizophrenic patients received intravenous dextro-amphetamine while on and off pimozide. The results provide evidence that negative symptoms and depressed mood in schizophrenia respond in part to intravenous challenges of dextro-amphetamine. Improvement in negative symptoms while on d-amphetamine correlated significantly with subsequent improvement in the same negative symptoms while on pimozide. These results do not support the Type II model of irreversible negative symptoms in schizophrenia in our patient sample. Changes in negative symptoms may be related to state dependent changes in the dopamine system, but noradrenergic mechanisms cannot be excluded either.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Adult
  • Clinical Trials as Topic
  • Depression / drug therapy
  • Depression / etiology
  • Dextroamphetamine / adverse effects
  • Dextroamphetamine / therapeutic use*
  • Double-Blind Method
  • Emotions / drug effects
  • Female
  • Humans
  • Male
  • Pimozide / therapeutic use
  • Psychiatric Status Rating Scales
  • Random Allocation
  • Schizophrenia / drug therapy*
  • Schizophrenic Psychology

Substances

  • Pimozide
  • Dextroamphetamine